Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Preventive Drugs Found to Stop New HIV Infections

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

2 September 2015. A large-scale study of preexposure prophylaxis or PrEP, the use of antiviral drugs to prevent HIV infection, found the practice prevented new HIV infections among Kaiser Permanente clients in San Francisco over a 32-month period. Results of the study . . . → Read More: Preventive Drugs Found to Stop New HIV Infections

FDA Approves Pediatric HIV Drug Formulation

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

5 June 2015. The U.S. Food and Drug Administration approved an application for a current HIV drug formulated to better treat infections in infants and young children, especially in limited resource regions. The formulation is a combination of lopinavir and ritonavir in . . . → Read More: FDA Approves Pediatric HIV Drug Formulation

GSK, UNC Chapel Hill Partner on HIV/AIDS Cure

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

11 May 2015. Pharmaceutical maker GlaxoSmithKline and University of North Carolina in Chapel Hill are establishing a joint research center and spin-off company to develop new treatments for HIV and AIDS. GSK says it plans to invest $20 million over 5 years . . . → Read More: GSK, UNC Chapel Hill Partner on HIV/AIDS Cure

Biotech, Universities to Test Hydrogel for Vocal Fold Scars

(A. Kotok)

28 August 2014. BioTime Inc., a biotechnology company in Alameida, California, is partnering with researchers at University of Wisconsin and Université catholique de Louvain in Belgium to test its hydrogels for treating vocal cord scarring, a voice problem that results from injury or disease. Financial terms of the collaboration were not disclosed.

. . . → Read More: Biotech, Universities to Test Hydrogel for Vocal Fold Scars

Early Trial Shows Gene Editing Potential to Treat HIV/AIDS

Bag of altered T-cells for infusion (University of Pennsylvania)

6 March 2014. Researchers from University of Pennsylvania, Albert Einstein College of Medicine, and the biotechnology company Sangamo BioSciences showed the company’s gene-editing technology could engineer the immune cells of HIV-positive patients to resist infection and decrease their viral loads. Results of the early-stage clinical . . . → Read More: Early Trial Shows Gene Editing Potential to Treat HIV/AIDS

Lab-On-Chip Diagnostics Company Lands $2.1M Angel Financing

Prototype cell analyzer (ChipCare Corp.)

ChipCare Corp., a spin-off company from University of Toronto in Canada developing hand-held diagnostics devices to replace fixed expensive lab equipment, secured $2.05 million in early stage angel financing. The deal combines investments from university, private-sector, and Canadian government sources, according to an announcement by Grand Challenges Canada, a . . . → Read More: Lab-On-Chip Diagnostics Company Lands $2.1M Angel Financing

Community Pharmacies Found Helpful in Encouraging HIV Tests

(National Institutes of Health)

Medical researchers at Albert Einstein College of Medicine of Yeshiva University in New York found local pharmacies can serve as venues to offer rapid HIV screening and get medical care for those who test positive. The team from Einstein College and its affiliated Jacobi Medical Center in the Bronx published . . . → Read More: Community Pharmacies Found Helpful in Encouraging HIV Tests

Algorithm Identifies HIV Antibodies For Vaccine Design

X-ray crystallography image showing antibody in green binding to vulnerable area (yellow) of HIV-1 virus (red). Courtesy: Structural Biology Section, NIAID

Biologists at National Institute of Allergy and Infectious Diseases (NIAID), part of National Institutes of Health, developed a mathematical model to highlight antibodies that neutralize viruses in people with HIV, which can help . . . → Read More: Algorithm Identifies HIV Antibodies For Vaccine Design

NIH Stops HIV Vaccine Immunizations in Clinical Trial

National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will stop testing an HIV vaccine candidate, after interim results showed the vaccine stopped neither HIV infections nor the amount of HIV in the blood. The HVTN 505 study, a phase 2 clinical trial of safety and efficacy begun in . . . → Read More: NIH Stops HIV Vaccine Immunizations in Clinical Trial

Mylan Acquires Generic Injectables Manufacturer for $1.6B

Mylan Inc., a producer of generic and specialty branded drugs in Pittsburgh, will acquire Agila Specialties in Bangalore, India, a developer of generic inectable drugs and division of Strides Arcolab Ltd. Mylan will pay $1.6 billion cash for Agila Specialties, with up to $250 million in contingent payments possible later on.

Mylan offers some 1,100 . . . → Read More: Mylan Acquires Generic Injectables Manufacturer for $1.6B